Abstract
BackgroundProgrammed cell death protein (PD-1) inhibitor immunotherapy is being increasingly used in oncology, but may cause immune-related adverse events (irAEs) resembling classical rheumatic and non-rheumatic autoimmune diseases. While oncological response...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
